Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Senesco Technologies has contracted with France-based Polyplus-transfection to supply Polyplus's 'in vivo-jetPEI' for systemic delivery of Senesco's combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.
Subscribe to our email newsletter
Senesco has previously reported positive preclinical in vivo results using its combination siRNA and plasmid delivered with ‘in vivo-jetPEI’ against subcutaneous multiple myeloma tumors in immunodeficient mice.
Bruce Galton, president and CEO of Senesco, said: “This supply agreement will help Senesco move toward the necessary preclinical toxicology study and ultimately the planned clinical trial targeting multiple myeloma.
“Polyplus’s PEI technology is already being used in clinical oncology trials by other companies and we look forward to working with them and using their technology to deliver our Factor 5A technology.”